Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAMUNEX-C in severe COVID-19
NCT04480424Phase 2Completed
- Sponsor
- Grifols
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous immunoglobulin G in coronavirus disease 2019 (COVID-19), sponsored by Grifols. Started Sep 2020; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04480424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480424.